BridgeBio is substantially advanced this course of an novel therapy for cardiac amyloidosis, employing the investigational drug. Preliminary clinical data reveals significant outcomes for those suffering from this severe disease. This effort highlights BridgeBio's commitment to addressing unmet medical requirements in a heart disease arena. … Read More